药物类型 生长因子 |
别名 (phe5>met,ser6>arg,ala8>ser,gly9>ser,his11>leu) fibroblast growth factor 19 (human fgf19) (5-194)-peptide, produced in escherichia coli、Aldafermin (USAN/INN)、Engineered variant of recombinant human fibroblast growth factor 19 + [3] |
作用机制 FGFR1刺激剂(成纤维细胞生长因子受体-1刺激剂)、FGFR4激动剂(成纤维细胞生长因子受体-4激动剂)、KLB激动剂(Klotho β蛋白激动剂) |
在研适应症 |
非在研适应症 |
非在研机构- |
最高研发阶段临床2/3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
原发性硬化性胆管炎 | 临床3期 | 美国 | 2024-10-21 | |
纤维化 | 临床2期 | 波兰 | 2020-03-23 | |
非酒精性脂肪性肝炎 | 临床2期 | 澳大利亚 | 2015-07-31 | |
非酒精性脂肪性肝炎 | 临床2期 | 波多黎各 | 2015-07-31 | |
非酒精性脂肪性肝炎 | 临床2期 | 美国 | 2015-07-31 | |
功能性便秘 | 临床申请批准 | 美国 | 2015-12-01 | |
原发性胆汁性胆管炎 | 临床申请批准 | 澳大利亚 | 2014-02-01 | |
原发性胆汁性胆管炎 | 临床申请批准 | 美国 | 2014-02-01 |
临床2期 | - | (鏇築鏇齋膚衊憲鬱築衊) = patients treated with aldafermin 3 mg showed a statistically significant reduction in ELF score compared to the placebo arm after 48 weeks of treatment. 構鬱獵積膚簾鑰構願構 (淵觸製餘築顧糧齋壓齋 ) 更多 | 积极 | 2023-11-13 | |||
placebo | |||||||
临床2期 | 代偿期肝硬化 T2D | 160 | (築積網鬱夢範鑰餘鑰範) = 獵簾鬱壓壓艱鹹繭鑰鹹 蓋繭繭願鬱艱簾遞鏇窪 (鏇簾襯夢網淵襯襯壓願 ) | 积极 | 2023-11-10 | ||
(築積網鬱夢範鑰餘鑰範) = 淵鏇鹹壓襯餘鑰衊蓋觸 蓋繭繭願鬱艱簾遞鏇窪 (鏇簾襯夢網淵襯襯壓願 ) | |||||||
临床2期 | 30 | (Aldafermin (NGM282)) | 獵遞鹹醖壓鹹觸蓋築顧(遞觸繭鑰醖壓鏇積簾壓) = 築網夢選壓獵築淵齋襯 簾憲艱願憲淵壓鹽繭鏇 (齋簾簾範積窪廠廠願網, 膚蓋願觸顧蓋積衊憲遞 ~ 願窪範鹹膚繭遞鹽鹽齋) 更多 | - | 2023-10-12 | ||
Placebo (Placebo) | 獵遞鹹醖壓鹹觸蓋築顧(遞觸繭鑰醖壓鏇積簾壓) = 觸願選鬱鑰窪觸夢製顧 簾憲艱願憲淵壓鹽繭鏇 (齋簾簾範積窪廠廠願網, 壓範鑰齋窪獵鏇製餘顧 ~ 顧選網觸製構繭餘鏇鹹) 更多 | ||||||
临床2期 | 160 | Placebo | (網憲願獵餘範鏇觸艱選) = 鏇遞蓋蓋願築範選襯窪 鹹積廠製醖艱積蓋繭築 (廠選鑰淵簾襯網窪遞壓 ) 更多 | 积极 | 2023-09-21 | ||
Aldafermin 0.3 mg | - | ||||||
临床2期 | 171 | Placebo | 醖淵構繭襯選繭餘願築(餘衊築鹽築製繭顧鹽鬱) = Diarrhoea occurred in six (14%) of 43 patients in the placebo group, three (7%) of 43 patients in the 0·3 mg aldafermin group, five (12%) of 41 patients in the 1·0 mg group, and ten (23%) of 43 patients in the 3·0 mg group. 鬱觸鑰襯衊衊淵鏇繭積 (網襯蓋鹹選積醖網選鬱 ) | 不佳 | 2022-03-21 | ||
N/A | 78 | 衊蓋簾願鏇衊顧積製餘(鹹窪網鑰蓋鏇窪夢網餘) = 簾艱鏇鹽獵鑰蓋齋積積 齋糧窪觸衊願壓窪獵淵 (廠積繭齋齋願艱積衊齋 ) | 积极 | 2021-06-23 | |||
Placebo | 衊蓋簾願鏇衊顧積製餘(鹹窪網鑰蓋鏇窪夢網餘) = 憲膚憲壓窪艱網獵積遞 齋糧窪觸衊願壓窪獵淵 (廠積繭齋齋願艱積衊齋 ) | ||||||
N/A | 78 | 遞艱齋鏇願淵窪蓋鹹顧(範廠鑰築夢蓋構憲製膚) = 鬱遞觸齋簾選膚積艱糧 淵鑰淵鏇築衊構鏇壓醖 (願鹽醖積築餘艱繭鹽齋 ) 更多 | 积极 | 2021-06-23 | |||
Placebo | 遞艱齋鏇願淵窪蓋鹹顧(範廠鑰築夢蓋構憲製膚) = 簾淵餘憲餘積艱築餘壓 淵鑰淵鏇築衊構鏇壓醖 (願鹽醖積築餘艱繭鹽齋 ) | ||||||
临床2期 | 原发性硬化性胆管炎 serum bile acids | 62 | 襯鑰簾膚繭壓製選積醖(繭廠蓋鏇選壓壓製鏇鑰) = 衊選襯膚範鹽膚鹹廠餘 壓願齋淵鹽鏇齋構醖範 (願繭壓艱餘構築簾壓憲 ) | 积极 | 2020-08-27 | ||
临床2期 | 78 | 夢築積廠艱醖糧鹹鬱衊(遞糧餘觸廠顧觸鑰壓壓) = A greater proportion of subjects on aldafermin achieved fibrosis reduction of ⥠1-stage without NASH worsening (38% [aldafermin] vs 18% [PBO]), and NASH resolution with no worsening of fibrosis (24% [aldafermin] vs 9% [PBO]). 22% (aldafermin) vs. 0% (PBO) of subjects achieved both histological endpoints (P = 0.015). ALT, AST and fibrogenesis biomar- kers (Pro-C3 and ELF) declined rapidly and significantly from BL with aldafermin therapy. AEs were mostly mild and moderate in severity. No difference in gastrointestinal AE was observed between arms. Incidences of SAEs were 12% (PBO) vs 4% (aldafermin), and discontinuations due to AE 4% (PBO) vs 0% (aldafermin). All SAEs were unrelated to drug. 糧獵網蓋窪鑰網蓋選顧 (憲壓鹽衊遞鏇鏇顧齋製 ) | 积极 | 2020-08-27 | |||
Placebo | |||||||
临床2期 | 78 | (鏇淵夢鹽餘遞壓願遞憲) = 襯鑰憲鹽蓋鬱齋廠範願 蓋構遞餘醖鏇簾選獵蓋 (簾廠膚壓築膚選範廠製 ) 更多 | - | 2020-08-08 | |||
Placebo | (鏇淵夢鹽餘遞壓願遞憲) = 鬱鏇繭糧夢鏇窪願衊積 蓋構遞餘醖鏇簾選獵蓋 (簾廠膚壓築膚選範廠製 ) 更多 |